Hard To Treat Diseases (HTDS) Recapi...( BELGRADE Serbia Jan. 9 / Hard to Trea...),Health

BELGRADE, Serbia, Jan. 9 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com the company having recently completed a merger with Slavica Bio Chem (Formerly ReNuYu Biochem) intends to recapitalize to 5 billion shares to pay for the Slavica merger and the pending China Bio Chem merger. Consideration for Slavica is 300 million non-dilatable restricted shares to be distributed amongst all doctors involved in Belgrade Serbia research. Key medical consultants and X ReNuYu management will receive stock options at a .03c strike price for up to 9% of the company common stock.

At present the company stock formulation details are as follows: Number of Common Shares Authorized: 1,200,000,000. Number of Common Shares Outstanding 862,581,959. Number of Restricted Shares: 480,091,291 Number of Preferred Shares Authorized: 25,000,000. Number of Preferred Shares Issued: None. The company intends to issue 10,000 convertible preferred shares to secure debt financing of about 1.5 million dollars.

The company's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV. Other interests include an on line cosmetics company.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at